Enveric Biosciences, Inc. financial data

Symbol
ENVB on Nasdaq
Location
4851 Tamiami Trail N, Suite 200, Naples, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 312 % +28.5%
Return On Assets -241 % -46.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.25M shares -63.6%
Common Stock, Shares, Outstanding 3.03M shares -61.6%
Entity Public Float 4.9M USD -31%
Common Stock, Value, Issued 30.3K USD -61.6%
Weighted Average Number of Shares Outstanding, Basic 2.6M shares +413%
Weighted Average Number of Shares Outstanding, Diluted 2.6M shares +413%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.78M USD -7.94%
General and Administrative Expense 5.9M USD +2.33%
Operating Income (Loss) -9.96M USD +2.39%
Nonoperating Income (Expense) 46.6K USD -88.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.94M USD +5.95%
Income Tax Expense (Benefit) 1.73K USD
Net Income (Loss) Attributable to Parent -9.94M USD +6.15%
Earnings Per Share, Basic -8 USD/shares +93.6%
Earnings Per Share, Diluted -8 USD/shares +93.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 3.31M USD -40.1%
Property, Plant and Equipment, Net 241K USD -40.5%
Operating Lease, Right-of-Use Asset 9.61K USD -92.1%
Intangible Assets, Net (Excluding Goodwill) 169K USD
Goodwill 253K USD -82.8%
Assets 3.55M USD -41.4%
Accounts Payable, Current 1.04M USD +126%
Accrued Liabilities, Current 223K USD +26.3%
Liabilities, Current 1.36M USD +111%
Accumulated Other Comprehensive Income (Loss), Net of Tax -574K USD -1.24%
Retained Earnings (Accumulated Deficit) -111M USD -9.86%
Stockholders' Equity Attributable to Parent 2.18M USD -59.6%
Liabilities and Equity 3.55M USD -41.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.39M USD +7.96%
Net Cash Provided by (Used in) Financing Activities 4.45M USD -33.2%
Net Cash Provided by (Used in) Investing Activities -5.17K USD +99%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 3.03M shares -61.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.05M USD -49.5%
Deferred Tax Assets, Valuation Allowance 13.7M USD +6.37%
Depreciation 162K USD -6.18%
Payments to Acquire Property, Plant, and Equipment 5.17K USD -99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.95M USD +6.27%
Operating Lease, Liability, Current 9.61K USD -91.3%
Deferred Tax Assets, Operating Loss Carryforwards 12M USD +10.3%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 114M USD +6.35%
Amortization of Intangible Assets 169K USD -0.01%
Share-based Payment Arrangement, Expense 1.15M USD -18.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%